title: Liver and gut mucosa acetylation of mesalazine in healthy volunteers.
abstract: OBJECTIVE
  The aim of this investigation was to identify which part of a dose mesalazine is acetylated by enzymes in the gut wall during the absorption process, and which part by the liver enzymes after absorption.
  
  
  METHODS
  This study was based on data from four bioequivalence studies of different formulations of tablets (gastro-resistant single dose 500 mg (n = 24) and prolonged-release tablets (single dose 1000 mg, n = 18; multiple dose 1000 mg t.i.d. six days n = 28), suppositories (single 500 mg dose, n = 24) and a study with two i.v. administrations of 100 and 250 mg mesalazine (n = 6). In total, 200 administrations were carried out and plasma concentration-time curves obtained and analyzed. There was a large variability in the absorption of mesalazine for all formulations. The plasma concentration-time curves of parent drug and metabolite acetylmesalazine run nearly parallel, independent of the formulation and the dose. Plasma and urine mesalazine and acetylmesalazine concentrations were determined according to validated methods using HPLC analysis with coulometric or mass-spectrometric detection.
  
  
  RESULTS
  As a result of the large variations in release and absorption of mesalazine in the pharmaceutical formulations and administrations, it was possible to demonstrate that acetylation occurs in the gut wall and in the liver. By comparing oral and rectal data to intravenous data, it was possible to indicate where (and to what extent) acetylation occurs in the gut wall, in the liver, or both. Rectal administration of a mesalazine suppository and intravenous administration results in hepatic acetylation. Oral administrations of mesalazine results in both gut wall and hepatic acetylation. Acetylation by the gut wall amounts to 30% of the dose for gastroresistant tablets and to 40% of the dose for prolonged-release tablets.
authors.affiliation: Institute for Anaesthesiology, Academic Hospital Nijmegen Sint Radboud, The Netherlands.
authors.forename: T B
authors.initials: TB
authors.lastname: Vree
authors.forename: E
authors.initials: E
authors.lastname: Dammers
authors.forename: P S
authors.initials: PS
authors.lastname: Exler
authors.forename: F
authors.initials: F
authors.lastname: Sörgel
authors.forename: S
authors.initials: S
authors.lastname: Bondesen
authors.forename: R A
authors.initials: RA
authors.lastname: Maes
mesh_terms: D000107:Acetylation; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000493:pharmacokinetics*; D019540:Area Under Curve; D018592:Cross-Over Studies; D006801:Humans; D007413:Intestinal Mucosa / Q000378:metabolism*; D008099:Liver / Q000378:metabolism*; D019804:Mesalamine / Q000008:administration & dosage / Q000493:pharmacokinetics*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D019804:Mesalamine